PTSM: Pharmaceutical Technology Sourcing and Management
This new pharmaceutical stability storage facility will enable the company to expand its analytical and formulation offerings to the pharmaceutical and biotech industries.
Intertek has opened a new 8000-square-feet, 190,000-liter pharmaceutical stability storage facility in Royston, United Kingdom. This new GMP-compliant facility will enable the company to expand its analytical and formulation offerings to the pharmaceutical and biotech industries. As part of Intertek’s wider investment program in global pharmaceutical capabilities, it also complements the company’s existing product development services for pharmaceuticals, biologics, medical devices, as well as other sectors such as consumer healthcare and nutraceuticals.
This new pharmaceutical stability storage facility increases Intertek’s stability storage capacity and will enable clients to establish recommended storage conditions with a state-of-the-art environmental monitoring system. Mark Hammond, laboratory director, commented in a press statement, that “this new facility, integrated with our scientists’ experience and knowledge of pharmaceutical testing, will bring a range of storage solutions with options for client bespoke conditions and risk management storage to meet the increased demands from our global clients.”
GMP stability testing is a key part of Intertek’s pharmaceutical development services. Intertek’s global International Conference on Harmonization (ICH) stability storage and testing locations also include Manchester (UK), Whitehouse, (New Jersey, US), and Melbourne (Australia).
Source: Intertek
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.